Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (HK:8329)
:8329
Want to see HK:8329 full AI Analyst Report?
8329 Stock Chart & Stats
HK$0.16
>-HK$0.01(-0.63%)
At close: 4:00 PM EST
HK$0.16
>-HK$0.01(-0.63%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.20
Previous CloseN/A
Volume90.00K
Average Volume (3M)330.65K
Market Cap
HK$176.19M
Enterprise ValueHK$37.36M
Total Cash (Recent Filing)HK$209.45M
Total Debt (Recent Filing)HK$73.02M
Price to Earnings (P/E)―
Beta0.16
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.51%
Share Statistics
EPS (TTM)<0.01
Shares Outstanding426,000,000
10 Day Avg. Volume371,000
30 Day Avg. Volume330,653
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative LeverageLow debt levels (debt-to-equity ~0.10–0.13) materially reduce financial risk and interest burden, giving management durable flexibility to fund operations, absorb earnings shocks, and prioritize R&D or capex. This conservatism supports stability over the next several quarters.
Stronger Cash Generation (2025)A meaningful rebound in operating cash flow and strongly positive free cash flow in 2025 indicate improved cash conversion and working-capital management. This cash generation bolsters liquidity, funds reinvestment or dividends, and provides a buffer while earnings recover.
Operating Earnings ResilienceDespite a reported net loss, the business produced positive operating earnings in 2025, showing core operations can still generate operating profit. That suggests underlying gross economics or cost control in core activities remain viable for a sustained recovery if top-line stabilizes.
Bears Say
Margin Compression And Net LossMaterial gross-margin erosion to ~29% and a swing to a net loss erode the company’s earnings cushion, weakening returns and reducing reinvestment capacity. Sustained margin compression would impair free cash flow durability and constrain recovery without structural cost or pricing fixes.
Declining Revenue TrendBack-to-back revenue weakness, including ~4.7% decline in 2025, signals demand or share pressure. Persistent top-line decline undermines operating leverage, makes margin recovery harder, and limits the company’s ability to scale R&D or SG&A efficiently over the medium term.
Asset/equity Erosion And Cash VolatilityA reduction in equity and assets in 2025 combined with historically volatile cash flows raises concern about balance-sheet resilience. Asset base erosion can limit financing options, while cash volatility reduces confidence in sustaining positive free cash flow across future cycles.
8329 FAQ
What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.09 and its highest was HK$0.20 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$176.19M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Aug 07, 2026 which is in 55 days.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.164 which represents an annual dividend yield of 3.51%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.21%
12-Months-Change
Fundamentals
Return on Equity
-6.17%
Trailing 12-Months
Asset Growth
-20.91%
Trailing 12-Months
Company Description
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Its manufacturing operations encompass herbal medicines, generic drugs, and medical devices. This entity operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Essex Bio-Technology
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CanSino Biologics, Inc. Class H
―
Ab&B Bio-Tech CO., LTD. JS Class H
―